研究業績

論文・出版

2019年


Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study


Takayuki Ueno, Norikazu Masuda, Nobuaki Sato, Shoichiro Ohtani, Jun Yamamura, Nobuki Matsunami, Masahiro Kashiwaba, Toshimi Takano, Masato Takahashi, Koji Kaneko, Shinji Ohno, Satoshi Morita, and Masakazu Toi


Japanese Journal of Clinical Oncology, 2020, 50(1)3–11 doi: 10.1093/jjco/hyz119 Advance Access Publication Date: 10 December 2019

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study


Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Yutaka Yamamoto, Daisuke Yotsumoto, Masakazu Toi and Shinji Ohno


Breast Cancer 27, 389–398 (2020), doi: 10.1007/s12282-019-01029-3

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer (JBCRG-09)


Hiroshi Ishiguro, Norikazu Masuda, Nobuaki Sato, Kenji Higaki, Takashi Morimoto, Yasuhiro Yanagita, Makiko Mizutani, Shoichiro Ohtani, Koji Kaneko, Tomomi Fujisawa, Masato Takahashi, Takayuki Kadoya, Nobuki Matsunami, Yutaka Yamamoto, Shinji Ohno, Toshimi Takano, Satoshi Morita, Sachiko Tanaka-Mizuno, and Masakazu Toi


Breast Cancer Research and Treatment 180, pages715–724(2020), doi: 10.1007/s10549-020-05590-w

Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer (JBCRG-12/15)


Hiroshi Ishiguro, Shinji Ohno, Yutaka Yamamoto, Shintaro Takao, Nobuaki Sato, Tomomi Fujisawa, Takayuki Kadoya, Katsumasa Kuroi, Hiroko Bando, Yasufumi Teramura, Hiroji Iwata, Shiro Tanaka, Masakazu Toi


Breast Cancer. 2019 Sep;26(5):535-543. doi: 10.1007/s12282-019-00952-9. Epub 2019 Feb 7.

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks’ exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study (JBCRG-11TC)


Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi


Cancer Med. 2019 Sep;8(12):5468-5481. doi: 10.1002/cam4.2423. Epub 2019 Jul 30.

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR


Takayuki Ueno, Norikazu Masuda, Shunji Kamigaki, Takashi Morimoto, Shigehira Saji, Shigeru Imoto, Hironobu Sasano, Masakazu Toi


International Journal of Molecular Science 2019, 20(4), 984; doi: 10.3390/ijms20040984

任意団体JBCRG 研究業績